Thomas M. Habermann, M.D.
Professor of Medicine, Mayo Clinic College of Medicine
Consultant, Division of Hematology

VIDEO:

MAYO STAFF:  Access this pre-recorded session on the Video Exchange website.  
MAYO CLINIC CARE NETWORK:  You are being directed here from the video housed in the Care Network portal.

RELEASE:  October 11, 2017
EXPIRATION:  December 31, 2018 (Credit is not available after this expiration date.)

LEARNING OBJECTIVES:

• Describe the natural history, outcomes, and complications of treated hodgkin lymphoma
• Describe the standard treatment modalities and approaches for the management of Hodgkin lymphoma
• Describe the new biologic approaches in the management of hodgkin lymphoma
• Recognize contributions of the Mayo Clinic Lymphoma Group to the field of Hodgkin lymphoma since 1986

ACCREDITATION:
Mayo Clinic College of Medicine and Science is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  

Mayo Clinic College of Medicine and Science designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

INSTRUCTIONS:

• Click the Take Course button below.
• Participate in the quiz.  Participants must pass by a minimum of 80%, 1 re-take is allowed.  Quizzes will have 2-5 questions.
• Complete the evaluation. 

TRANSCRIPT:
This credit will appear on your Transcript for permanent record.  To access your transcript, visit My Account, My Activities, RSS Transcript.

DISCLOSURE SUMMARY:  As a Jointly Accredited Provider by ACCME, ACPE, and ANCC, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity.  Safeguards against commercial bias have been put in place.  Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.  Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

Medical Grand Rounds Planning Committee

Dr. Morie Gertz –

• Speaker's Bureau - Research to Practice, Med Learning Group
• Grant/Research Support - IONIS, Prothena Therapeutics, Annexon Biosciences, Novartis, Alnylam Pharmaceuticals
• Honoraria - Celgene, Research to Practice, Med Learning Group, National Cancer Institute of Frederick, Sandoz Inc. (a Novartis Company), GlaxoSmithKline

Dr. Christina Dilaveri – None
Dr. Karna Sundsted – None
Dr. Amy Williams - None
Dr. Amy Oxentenko – None
Dr. Justin Fiala - None
Dr. Korosh Sharain - None
Jeanine Kiefer – None
Lisa Sikkink - None 

Medical Grand Rounds Advisory Group
Dr. Christina Dilaveri – None
Dr. Karna Sundsted – None
Dr. John Bundrick – None
Dr. Colin West – None
Dr. Aaron Mansfield –

• Consultant: Genentech
• Grant/Research Support: Novartis

Dr. John Kisiel –

• Grant/Research Support: Exact Sciences
• Other - Patents applied for - Jointly with Mayo Clinic and Exact Sciences.  Potential for royalties

Jeanine Kiefer – None

Presenter - Dr. Habermann

Financial Relationships:

• None

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:

• Novartis, Kite - Car-T cells, Everolimus
• Bristol-Meyers Squibb - Nivolumab
• Merck - Pembrulizumab
• Genentech, Roche - Rituximab
• Rituximag nanoparticle and Tipirarnib

QUESTIONS?

MAYO STAFF:   Contact Jeanine Kiefer at 8-1952
MAYO CLINIC CARE NETWORK MEMBERS:  Contact cme@mayo.edu  

SUPPORT LOCATION: 

Minnesota